LaSOM 335, active against bladder cancer cells, interferes with Let‐60 ( h Ras ) and reduces CD 73 expression/activity
Chemical Biology & Drug Design · 2023
DOI: 10.1111/cbdd.14273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2023. Verfasst von Luciano Porto Kagami und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Síntese Orgânica Medicinal - LaSOM®, Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal …. Hauptthemen laut MEDLINE: Genes, ras, Urinary Bladder Neoplasms, Biphenyl Compounds, Pyrimidinones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Bladder cancer is the fourth most common malignancy in men. It can present along the entire continuum of severity, from mild to well‐differentiated disease to extremely malignant tumors with low survival rates. Human RAS genes are the most frequently mutated oncogenes in human cancers, and the critical role of aberrant Ras protein function in carcinogenesis is well established. Therefore, considerable efforts have been devoted to the development of anti‐Ras inhibitors for cancer treatment. This study presents the biphenyl dihydropyrimidinone LaSOM 335 with high activity against T24 bladder cancer cells (IC 50 = 10.73 ± 0.53 μM) and selectivity of cytotoxicity for this cancer cell line compared to two non‐cancer cell lines investigated. Furthermore, we also show that this compound reduced vulvar development in the mutant let ‐60 gene of Caenorhabditis elegans . Let ‐60 is a homolog of the mammalian Ras gene. In addition, we observed that LaSOM 335 inhibits the enzymatic activity of CD73 and decreases CD73 expression. Possibly, this expression decrease is due to downstream EGFR signaling via the Ras–Raf–ERK pathway, that directly regulates CD73 expression via ERK1/2. Evidence suggests that non‐immunomodulating functions of CD73 play an equally important role for cancer cell survival, progression, and migration. Regarding we also notice that LaSOM 335 was safe in the in vivo model of C. elegans . The set of these findings makes this biphenyl dihydropyrimidinone a promising candidate for further investigations in the bladder cancer field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratório de Síntese Orgânica Medicinal - LaSOM®, Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Faculdade de Medicina, Universidade Regional Integrada do Alto Uruguai e das Missões-URI, Erechim, Brazil.
- Departamento de Bioquímica, Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Graduation Program in Biochemistry, Laboratory of Biochemistry and Toxicology in Caenorhabditis elegans, Federal University of Pampa, Uruguaiana, Brazil.
- Laboratory of Toxicology (LATOX), Department of Analyses, Programa de Pós-Graduação em Ciências Farmacêuticas, Faculty of Pharmacy, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
ORCID-Profile: Luciano Porto Kagami, Itamar Luís Gonçalves, Gustavo Machado das Neves, Fabrício Figueiró, Solange Cristina Garcia, Daiana Silva Ávila, Ana Maria Oliveira Battastini, Vera Lucia Eifler-Lima
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Kagami, L. P., Gonçalves, I. L., da Silva, Á. C., Silva, A. C., das Neves, G. M., Göethel, G., Spillere, A., Dos Santos, M. R., Figueiró, F., Garcia, S. C., Ávila, D. S., Battastini, A. M. O., & Eifler-Lima, V. L. (2023). LaSOM 335, active against bladder cancer cells, interferes with Let‐60 ( h Ras ) and reduces CD 73 expression/activity. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14273
Vancouver
Kagami LP, Gonçalves IL, da Silva ÁC, Silva AC, das Neves GM, Göethel G, et al. LaSOM 335, active against bladder cancer cells, interferes with Let‐60 ( h Ras ) and reduces CD 73 expression/activity. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14273
BibTeX
@article{Kagami2023,
author = {Kagami, Luciano Porto and Gonçalves, Itamar Luís and da Silva, Álisson Coldebella and Silva, Aline Castro and das Neves, Gustavo Machado and Göethel, Gabriela and Spillere, Adriano and Dos Santos, Maitê Roxo and Figueiró, Fabrício and Garcia, Solange Cristina and Ávila, Daiana Silva and Battastini, Ana Maria Oliveira and Eifler-Lima, Vera Lucia},
title = {LaSOM 335, active against bladder cancer cells, interferes with Let‐60 ( h Ras ) and reduces CD 73 expression/activity},
journal = {Chemical Biology & Drug Design},
year = {2023},
doi = {10.1111/cbdd.14273}
}
EUVIMED